Exicure
Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Learn more
Launch date
Employees
Market cap
AUD4.1m
Enterprise valuation
AUD15m (Public information from Sep 2024)
Share price
$3.93 XCUR
Chicago Illinois (HQ)
Authorizing premium user...